The National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technology in Health (CADTH) are collaborating to offer parallel scientific advice to the life sciences industry.
The two health technology assessment organisations have a lot in common in terms of how they evaluate new treatments and value the opportunity for early engagement with companies targeting the English and Canadian markets.
The advice will help companies prepare for future health technology assessments by answering their questions and providing key insight on their clinical and health economic development plans.
This follows NICE’s recently announced collaboration with the Ethical Medicines Industry Group.
“We recognise the inherent difficulties faced by developers in designing clinical trial programmes that meet the precise requirements of multiple international markets,” said Jeanette Kusel, Director of NICE Scientific Advice.
“This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”
Michelle Mujoomdar, Acting Vice President, Evidence Standards, CADTH, added: “This exciting new international collaboration between two established HTA bodies will help pharmaceutical companies develop relevant evidence for CADTH and NICE while streamlining the process of obtaining advice in two distinct markets.”
According to a release, applications from pharmaceutical companies for parallel scientific advice are now being accepted.